

CLAIMS

1. The use of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an amount of an anti-IL-1 α antibody effective to treat a symptom of hidradenitis suppurativa in a human subject for the manufacture of a medicament for treating hidradenitis suppurativa in a human subject having lesions associated with hidradenitis suppurativa, wherein the anti-IL-1 α antibody is a monoclonal antibody that comprises all of the complementarity determining regions of MABp1.

2. The use of the pharmaceutical composition according to claim 1, wherein the monoclonal antibody is an IgG1.

3. The use of the pharmaceutical composition according to claim 2, wherein the monoclonal antibody is MABp1.

4. The use of the pharmaceutical composition according to any preceding claim, wherein the pharmaceutical composition is for administration at a dose of between 1-20 mg/kg body weight.

5. The use of the pharmaceutical composition according to claim 4, wherein the pharmaceutical composition is for repeated administration, wherein the repeated administration is semi-weekly, weekly, biweekly, tri-weekly, semi-monthly, once every three weeks, monthly, bi-monthly.

6. The use of the pharmaceutical composition according to any preceding claim, wherein the K_a of the antibody is at least $1 \times 10^9 \text{ M}^{-1}$.

7. The use of the pharmaceutical composition according to claim 1, wherein the subject's hidradenitis suppurativa clinical response (HiSCR) score is improved after administration of the pharmaceutical composition.

8. The use of the pharmaceutical composition according to any one of the preceding claims, wherein the median size of the subject's hidradenitis suppurativa lesions is reduced after administration of the pharmaceutical composition.

9. The use of the pharmaceutical composition according to claim 1, wherein the subject's pain associated with the subject's hidradenitis suppurativa lesions is reduced after administration of the pharmaceutical composition.

10. The use of the pharmaceutical composition according to claim 1, wherein the subject's time to new hidradenitis suppurativa lesions is increased after administration of the pharmaceutical composition.

11. The use of the pharmaceutical composition according to claim 1, wherein the hidradenitis suppurativa in the human subject has failed to resolve after treatment with tumor necrosis factor alpha inhibitors.

12. The use of the pharmaceutical composition according to any preceding claim, wherein the treatment reduces the number and/or size of inflammatory lesions, such as nodules, abscesses or draining fistulas.